Good MorningEquities pulled back again on Tuesday following another round of hotter than expected inflation data. The PPI came in at 0.8% for the month, up 0.2% from October and 0.3% hotter than forecast. The figure is coupled with high core readings and the hottest YOY increases on record.
If there was any doubt the FOMC would be raising interest rates sooner than expected this news should lay those doubts to rest. The CME Fedwatch tool is pricing in a near 60% chance the first hike will come by May and a 70% chance for two .25% interest rate hikes by June so today’s FOMC meeting is more important than ever. The Fed is expected to accelerate the taper and move the timeline for rate hikes forward.
Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Markets | |
When you have a precise retirement savings number you'd like to achieve, it takes dedication and consistent investing to get there.
Luckily, Americans have confidence that they'll achieve their retirement goals. Three in four workers (73%) believe they can fully retire with a comfortable lifestyl... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Consumer Discretionary | | Casino operator Las Vegas Sands (NYSE: LVS) stock has fallen down to its COVID-19 low levels in recent weeks. The epicenter stock has seen renewed fears of China intervention with the Macau gambling industry as well as COVID-19 protocols tightening again. Gambling is one of the few industries that d... Read the Full Story |
|
Retail/Wholesale | |
Since the early days of the pandemic, the reopening trade has been a popular way play the anticipated turnaround in beaten up, economically sensitive stocks.
Some groups like restaurants and retailers have recovered much if not all of their 2020 losses. Others like airlines and hotels have many m... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Technology | |
Just when many companies began anticipating welcoming employees back to the office, the Omicron variant has caused some to reconsider. Google (NASDAQ:GOOGL) and Ford (NYSE:F) are two examples of companies that just announced they are delaying their return-to-work plans.
But the repercussions of... Read the Full Story |
|
Medical | |
3 Low-Volatility Stocks Showing Strength in a Weak Market
Market sentiment can change in the blink of an eye, and that’s quite evident in the recent selling pressure we’ve seen occurring in the high growth areas. A lot of this likely has to do with the upcoming Federal Reserve meeting... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Auto/Tires/Trucks | |
Rivian or Lucid Motors, Both Look Good For the Long Haul, Which is Best Right Now?
Electric vehicle (EV) stocks remain one of the most intriguing plays for investors. After a sharp sell-off earlier this year, stocks of EV companies are beginning to reinflate. And two of the hottest stocks in the ... Read the Full Story |
|
Markets | |
It’s Time To Get Ready For Q4 2021 Earnings
With the S&P 500 (NYSEARCA: SPY) Q4 earnings cycle having already started, it is time to get ready for the peak of the season. The peak is still quite a few weeks away but it pays to be ready. So far, reports from names like Oracle (NYSE: ORCL... Read the Full Story |
|
Markets | | Fiber optics providers Ciena (NYSE: CIEN) and Clearfield (NASDAQ: CLFD) are trading at multi-year highs as network upgrades spur revenue growth.
Although they operate in similar industries and are well established, these are quite different companies.
With a market capitalization of $11.49 billi... Read the Full Story |
|
Auto/Tires/Trucks | |
Winnebago Is A Buy Before Earnings
To answer the question, are insiders buying Winnebago (NYSE: WGO) ahead of earnings, we must say yes, they are, or at least one did. Director Maria Favlana Blase bought 364 shares for a grand total of $24,053 at the end of October capping off a year in which mo... Read the Full Story |
|
Markets | |
Hexo Hits New Low In Wake Of Q1 Earnings
Hexo (NYSE: HEXO) reported its Q1 earnings and provided a forecast for profitability that has shares of the stock on the move. The caveat is that shares are moving lower right now and are just off the new low set in the wake of the report. As good as the ... Read the Full Story |
|
The Early Bird Stock Of The Day Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. | | View Today's Stock Pick |
|
